Recent studies have indicated that EVs-PD-L1 can be more effective than tumor cell-associated PD-L1 in expediting escape from antitumor immunity since EVs can be prevalent in body fluids and may bind to their recipient cells more simply than tumor cells [60]. The gene discussed is CD274; the disease is neoplasm.